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Cancer initiation, progression, and the emergence of ther-
apeutic resistance are evolutionary phenomena of clonal
somatic cell populations. Studies in microbial experi-
mental evolution and the theoretical work inspired by
such studies are yielding deep insights into the evolu-
tionary dynamics of clonal populations, yet there has
been little explicit consideration of the relevance of this
rapidly growing field to cancer biology. Here, we examine
how the understanding of mutation, selection, and spatial
structure in clonal populations that is emerging from
experimental evolutionmay be applicable to cancer. Along
theway, we discuss some significantways inwhich cancer
differs from themodel systemsused in experimental evolu-
tion. Despite these differences, we argue that enhanced
prediction and control of cancer may be possible using
ideas developed in the context of experimental evolution,
and we point out some prospects for future research at
the interface between these traditionally separate areas.
Introduction
In the 36 years since Peter Nowell’s seminal paper on the
clonal evolution of tumor cell populations [1], it has become
apparent that a comprehensive theory of cancer must
include a substantial amount of the theory of evolution
(reviews [2–5]). Roughly the same time interval has seen
the remarkable rise of direct experimental approaches to
evolution in which microbial populations are propagated
for many generations and their evolution in real time is
observed and analysed (reviewed in [6]). The burgeoning
field of microbial experimental evolution has generated a
rich empirical and theoretical literature that is largely focused
on the evolution of clonal populations: i.e., populations lack-
ing intergenomic recombination. Because recombination
between somatic cells is rare to nonexistent, theory and
experimental work in asexually evolving microbial popula-
tions can, in principle, be applied to the understanding
of cancer. Although connections between cancer and the
phenomena observable in microbial evolution experiments
have occasionally been drawn [7–17], to date there has
been no attempt to assess the overall relevance of experi-
mental evolution to cancer biology. We believe such an1Institute for Evolutionary Biology and Environmental Sciences,
University of Zurich, Winterthurerstrasse 190, 8057 Zurich,
Switzerland. 2Lankenau Institute for Medical Research, 100 Lancaster
Ave., Wynnewood, PA 19096, USA. 3Department of Biology,
University of New Mexico, Albuquerque, NM 87131-0001, USA;
Centro de Matema´tica e Aplicac¸o˜es Fundamentais, Department of
Mathematics, University of Lisbon, 1649-003 Lisbon, Portugal.
4Center for Evolution and Cancer, Helen Diller Family Comprehensive
Cancer Center, Department of Surgery, University of California, 2340
Sutter Street, PO Box 1351, San Francisco, CA 94115, USA.
5Department of Biology, University of Pennsylvania, 415 S. University
Avenue, Philadelphia, PA 19104-6018, USA.
*E-mail: kathleen.sprouffske@ieu.uzh.ch (K.S.), lmf.merlo@gmail.com
(L.M.F.M.)assessment is timely: on the one hand, increased awareness
of experimental evolution and its related theory on the part
of cancer researchers and clinicians may hold benefits for
the understanding and treatment of cancers; on the other
hand, there is value in anticipating the limits of experimental
evolution approaches as applied to cancer.
Early studies of evolution assumed, perhaps following
Darwin [18], that its course is too slow to observe directly
and must therefore be inferred indirectly. Indeed, the very
fact of evolution and the major outlines of its history were
established largely by indirect inference from fossils, bio-
geographical patterns, and anatomical comparisons among
extant taxa (reviewed in [19]). Into the second half of the
20th century, most empirical studies of evolution focused
on comparison of patterns of variation and divergence within
and between populations and species rather than on real-
time analysis of evolutionary change. There was, however,
a growing awareness that evolution could also be observed
and studied directly, both in the field with sufficient effort [20]
and in the laboratory [21–26]. The past two decades have
seen a rapid expansion of experimental studies of evolution
of many kinds, but in particular of those usingmicrobial pop-
ulations in the laboratory (reviews in [6,27,28]). Microbial
evolution experiments have, in turn, stimulated advances in
theory related to the evolution of clonal populations (e.g.,
[10,13,29–41]). Our goal here is to relate the increasingly
sophisticated literature on microbial experimental evolution
to cancer biology.
Cancer certainly has organism-level evolutionary con-
sequences for humans and other taxa. Selection at the
organismal level, for example, has arguably favored the
maintenance of low somaticmutation rates (except in the im-
mune system) and the evolution of tumour suppression
mechanisms [42–46]. However, in this review we focus on
processes at a lower level of organisation: namely, the evolu-
tionary dynamics that occur within the somatic cell popula-
tions of an individual organism and give rise to cancer. At
this level, cancers and experimental microbial populations
are potentially quite similar in that each evolves under muta-
tion, selection, genetic drift, migration, and varying amounts
of spatial structure in the absence of intergenomic recombi-
nation. (See Table 1 for a glossary of some common terms in
evolution and cancer.)
In a typical microbial evolution experiment, replicate pop-
ulations of an experimental organism (e.g., bacteria or yeast)
are founded from a single ancestral cell and propagated
either by transferring them periodically to fresh medium
or by supplying them continuously with fresh medium
(Figure 1A,B). The ancestor and intermediate stages in the
history of the populations are archived as frozen stocks
and revived for later analyses of fitness and phenotype
evolution. The investigator can control the environment,
the population size, the initial genetic state of the popula-
tions, and other variables of interest, in contrast to the situa-
tion in most natural populations. Because of the ease with
which experimental microbial populations can be propa-
gated and maintained, investigations of this kind can be
carried out for many thousands of generations: the iconic
example in the field is a set of 12 replicate Escherichia coli
populations that have been propagated since the late 1980s
for a current total of more than 50,000 generations [47].
Table 1. Common terms in evolution and cancer.
Cell lineage: A group of cells related by a common ancestral cell. A particular lineage may accumulate multiple mutations during cancer progression.
Clone: A group of cells, descended from a single common ancestral cell, that can share the same genetic lesions.
Beneficial mutation: A mutation that increases the fitness of the cell/organism. Note that in the case of cancer, mutations that are beneficial to cancer
cells are detrimental to the host.
Deleterious mutation: A mutation that decreases the fitness of the cell/organism. Lethal mutations are one type of deleterious mutation.
Driver: A beneficial mutation in a neoplasm that increases the fitness of the cell, causing the cell’s lineage to spread.
Epistasis: Interaction between genes. In a practical sense, this means that the effect of a particular mutation is dependent upon the genetic background
on which it occurs. For a thorough review of the many definitions and implications of epistasis in evolution, see [169].
Fitness (relative): Fitness is a function of an organism’s ability to survive and reproduce. Usually, relative fitness is measured in microbial experimental
evolution: for example, the growth rate of one genotype compared to that of a second, competing genotype.
Fixation: When a mutation in a population of cells/organisms spreads such that all individuals have the mutation.
Genetic drift: In genetic drift, clones (or genotypes) carrying amutation change in frequency due to stochastic processes rather than selection. Drift is of
particular importance in small populations.
Hitchhiking: The process by which a mutation that is genetically linked to a beneficial mutation can rise toward fixation with the beneficial mutation as it
expands through the population. Hitchhikers are usually neutral or of weak selective effect.
Mutator: A defective allele at a locus controlling genomic fidelity (e.g., replication or repair). Mutator alleles raise the mutation rate.
Neoplasm: A collection of abnormal somatic cells. In genetic terms, a neoplasm contains mutations compared to the germ line that render the cells pre-
cancerous or cancerous.
Neutral mutations:Mutations that have such small effects on fitness that they are not under selection. This occurs when, approximately, Nes < 1, where
Ne represents the size of the genetically evolving population (effective population size) and s represents the strength of selection for/against the
mutation.
Passenger: A neutral or slightly deleterious mutation that is genetically linked to a driver mutation. As the driver mutation sweeps to fixation in the
neoplasm, the passenger mutation goes along for the ride. In this way, genetic lesions that are not selectively advantageous may fix in a population of
neoplastic cells. See also ‘hitchhiking’.
Selective sweep: The process by which a beneficial mutation increases in frequency until it reaches fixation in a population.
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tal populations of microbes and cancer cell populations
(Figure 1). Like cancers, experimental populations initiate
from clonal ancestors: an initial tumourigenic mutation in
the case of a cancer; a single ancestral cell in the case of
an experimental population. Cancers evolve independently
in different individuals over hundreds or thousands of
somatic cell divisions [48]; as noted above, the evolution
of replicate experimental populations can be studied
over similar time spans. In the absence of intergenomic
recombination, all genetic variation in both situations must
arise as a consequence of mutation, and evolution can
be broadly characterised as a process of sorting among
lineages representing different genomic sequences (Fig-
ure 2). Deeper and even more interesting phenomenolog-
ical parallels also seem to apply. For example, there is
evidence for the evolution of high genomic mutation rates
in experimental microbial populations and in some
cancers [8].
Below, we discuss parallels between experimental evolu-
tion and cancer in more detail, placing empirical results
from both fields into the general framework provided by
evolutionary theory, especially as developed for clonal pop-
ulations in the past two decades. We begin with a broad
discussion of cancer and evolution in clonal populations.
We then focus, in turn, on methods of detecting selection
in neoplasms, mutation rates and their consequences for
cancer, spatial structure and cell–cell interactions, and the
evolution of drug resistance. We conclude by briefly de-
scribing a potential new approach to predicting cancer
progression based on general evolutionary theory.
Overview: Cancer and the Nature of Evolution in Clonal
Populations
The accumulation of genetic variants that originated initially
asmutations—whether single nucleotide changes or larger-
scale genomic alterations such as deletions, insertions, and
chromosomal rearrangements—underlies genetic evolution
in all populations, including the populations of somatic cellsthat can give rise to cancer. The most important mutations
for the study of cancer are those that release somatic cells
from constraints on proliferation and migration and thereby
allow their lineage to outcompete others in a multicellular
organism; these are often called ‘driver mutations’ in the
cancer literature (e.g., [49–51]). From a general evolutionary
perspective, suchmutations increase the capacity of an indi-
vidual cell to survive and reproduce (i.e., its relative fitness)
within a somatic cell population, and thus they may accu-
rately be regarded as beneficial mutations for the individual
cell despite their potential detrimental effects on the whole
organism.
The central fact of evolution in clonal populations is that
genetic variants from different genomic backgrounds cannot
be combined into a single genotype as in a sexual population
[52,53]; a clonal population can only give rise to such geno-
types via the occurrence of multiple mutations on a common
genomic background (Figure 2). The way in which beneficial
mutations in particular accumulate within clonal lineages
thus depends strongly on the rate at which they arise in
a population. If the supply rate of beneficial mutations is
low, then new mutations will tend to be temporally isolated
from one another in a clonal population (Figure 2A). Under
these circumstances, a lineage bearing a single new benefi-
cial mutation may spread through a somatic cell population,
replacing its members in what is termed a periodic selection
event or selective sweep in the evolution literature (reviewed
in [33]). Some time later, another such sweep may occur,
completely separate in time from the first sweep. On the
other hand, if the supply rate of beneficial mutations is
high, then multiple beneficial mutations will be present in
the population at any given time and the dynamics of clonal
evolution can be considerablymore complicated (Figure 2C).
In either case, the progressive accumulation of mutations
beneficial to individual cells within a somatic cell lineage
can cause that lineage to proliferate, resulting in a neoplasm
and potentially in cancer.
In populations of microbes or of somatic cells, the supply
rate of beneficial mutations is given by the product of the
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Figure 1. Experimental evolution and cancer.
(A) In serial transfer evolution experiments,
several replicate microbial populations are
seeded froma culture originating froma single
ancestral colony (derived from a single cell).
Thereafter, a small subsample of each repli-
cate population is regularly transferred into
fresh medium. Aliquots of the evolving popu-
lations are preserved at regular time intervals
for future analysis. (B) In evolution experi-
ments conducted in a chemostat, the number
of cells remains essentially constant. As fresh
medium is fed into the chemostat, waste
medium is removed. Cells can be sampled
repeatedly from the waste medium, allowing
for analysis of the population over time
(adapted from [170]). (C) Somatic cells within
individuals may evolve over time to become
cancerous. The ancestral genotype for each
neoplasm is the germ line genotype of the
individual with the neoplasm.
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arise. Both of these parameters are controllable in microbial
evolution experiments, and this has facilitated sophisticated
experimental investigations of clonal evolution in such pop-
ulations that greatly exceed the current phenomenological
power of in vivo cancer studies. Neither population size nor
mutation rate is under experimenter control in cancer inves-
tigations. Indeed, the size of the evolving population in
a neoplasm is an unresolved question and may be one of
the more important differences between experimental
microbial populations and cancer. In an experimental micro-
bial population, all cells have an equal opportunity to
contribute to the next generation. In a neoplasm, however,
the evolving population consists only of those cells that
can continue dividing, either because they have the capacity
to self-renew as ‘cancer stem cells’ ([54–58], but see [59–61]),
or because they have not terminally differentiated (e.g.,
[5,62–64]). Despite these caveats, it appears that the abso-
lute size of the evolving cell population in many neoplasms
can be quite large [65], and this suggests that, in at least
some cases, the evolutionary dynamics of cancer involves
multiple simultaneous driver mutations. We discuss some
further implications of this possibility below.
Of course, not all mutations are beneficial: the great
majority are likely to be either deleterious (decrease fitness)
or neutral (have no effect on fitness). In both neoplasms
and experimental populations, cell lineages bearing strongly
deleteriousmutations are very unlikely to persist and spread.
However, cell lineages bearing neutral mutations or weakly
deleterious mutations may persist and even spread in such
populations, either individually through genetic drift or as
a byproduct of fortuitous association with beneficial muta-
tions. The latter effect is particularly important in clonal
populations because all new mutations that occur in a
genome are genetically linked. Thus, a spreading beneficial
mutation (driver) can carry mutations present or arising on
its genetic background to high frequency in a processof ‘genetic hitchhiking’ (Figure 2C). In
a further extension of the transpor-
tation metaphor, hitchhiking mutations
are often referred to as ‘passenger
mutations’ in the cancer literature
(e.g., [50,51]).It is important to note here that whether and to what
degree a given mutation is neutral, deleterious, or beneficial
can depend on the genetic background, on the environment,
and even on interactions between the genetic background
and the environment. In this way, for example, mutations
that accumulate neutrally in a population may later be bene-
ficial if the environment changes [66]; or a mutation that
would not spread in a neoplasm on one genetic background
may do so in a different background. We discuss some
possible examples of such epistasis in cancer in the next
section. Finally, it is also possible that the beneficial effect
of amutation could depend negatively on the number of cells
carrying that mutation. Such density dependence is sug-
gested by the view of cancer cells as social cheaters in a
restraint-based economy [14].
Selection in Neoplasms
Given the central importance of selection on new mutations
to evolutionary theories of cancer, we turn next to a brief
discussion of methods for detecting selection and the nature
of the evidence that they provide. Perhaps the most direct
method for detecting selection — and certainly the most
directly relevant to cancer — is to look for parallel, function-
ally convergent mutational changes in populations that have
been evolving independently in identical conditions. Experi-
mental populations and cancers are well suited to this
method; because each experimental population and each
individual’s cancer evolves uniquely, we can look across
different populations or cancers to identify common genetic
lesions. This approach can distinguish mutations directly
under selection (drivers in cancer) from hitchhiker mutations
(passengers). The fact that p53 mutations occur in many
different types of cancers across different individuals [67],
for example, indicates that mutations at this locus are not
merely hitchhikers but actually confer a selective advantage
to cancer cells. Studies in experimental evolution have taken
the lead in using genome sequencing to identify parallel
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Figure 2. Dynamics of clonal evolution.
Several variations on a visualisation of clonal evolution originated by
Muller in 1932 [53] and reinterpreted by Crow and Kimura [171]. We
consider the fate of new mutations in a finite population of constant
size. Time is depicted on the x-axis beginning at an arbitrary instant
at which we assume that the population has no competing clones;
the population sizes of clones harbouring mutations that have arisen
since that instant are depicted on the y-axis. The total number of
evolving cells in this neoplasm is constant (as might occur in the early
stages of neoplastic progression), but the fraction of cells that have
a given genotype varies as mutations arise and then either expand or
are lost. The genotypes of clones are depicted to the right; darker
colours indicate clones harbouring increasing numbers of beneficial
mutations. (A) When new, beneficial mutations (‘+’) are rare, they are
likely to sweep to fixation in the population before the next beneficial
mutation arises. In this case, all the cells in the final population will
have the +1 and +2 mutations. (B) Beneficial mutations are thought to
be rarer than neutral mutations (‘o’); neutral mutations may hitchhike
to fixation with a beneficial mutation. In this case, all of the cells in
the population will have the neutral o1 and the beneficial +2 mutations,
as indicated on the lower right margin of the panel. Additional neutral
mutations may arise and expand in the population (e.g., o3), leading
to intrapopulation heterogeneity. It is also possible for neutral muta-
tions to arise and go extinct: two such mutations are illustrated here.
(C) When the beneficial mutation supply rate is high, several beneficial
mutations may arise in separate clones and compete, as depicted here
by the +1 and +2 beneficial mutations (and also the +3 and +4 beneficial
mutations). The competition between the clones may delay the fixation
of any one of the beneficial mutations and thus prolong intrapopulation
heterogeneity. Here, there are four distinct genotypes in the neoplasm.
(D) The time between new beneficial mutations will tend to be longer in
small populations than in large populations, given the same beneficial
mutation rate.
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R765mutational changes in replicate populations that have been
subjected to a common selective regime (e.g., [68–70]). As
human genome sequencing becomes more and more
affordable, the prevalence of this approach is increasing in
cancer research. Several recent studies, for example, have
used various deep sequencing and single-cell sequencing
approaches to investigate the clonal origin and genetic
heterogeneity of tumours and to identify candidate driver
mutations [71–76]. It is worth noting some caveats, however.
First, in contrast to replicate experimental populations,
individuals represent different genotypes. Such genotypic
differences could well result in different individuals taking
quite different genetic pathways to cancer. Second, and
also in contrast to the situation in experimental evolution,
individuals may represent very different environments for
tumour evolution (smokers vs. nonsmokers, for example),
again potentially affecting the pathway to cancer. Finally,
when common mutations (whether point mutations or
chromosomal rearrangements) are found across replicate
populations or cancers, these could in principle be due to
increased susceptibility to mutation in certain regions rather
than to selection. For example, it is well known that fragile
sites [77] tend to be mutated in certain cancers [77–79], but
it is unclear as to whether this is simply because of their
high mutation rates or also because such mutations are
selectively favored in neoplasms.
Various statistical tests for detecting selection on point
mutations in nucleotide sequence data sampled from natural
populations have been in use by evolutionary biologists
since around 1990 [80] (reviewed in [81,82]). In principle,
ratios of nonsynonymous to synonymous nucleotide substi-
tutions (dN/dS) and/or polymorphisms observed in homolo-
gous sequences within and between populations can be
used to infer ‘purifying selection’ against deleterious muta-
tions (dN/dS < 1), neutral evolution (dN/dS = 1), or ‘‘positive
selection’’ in favor of beneficial mutations (dN/dS > 1). Such
tests, however, are quite sensitive to certain demographic
assumptions, are often lacking in statistical power [83,84],
and are generally not suited to pinpointing the exact
functional changes under selection — something which is
obviously of great interest in cancer research. Furthermore,
most of these methods are based on detecting deviations
from equilibrium expectations under the forces of mutation,
selection, and genetic drift and thus may not apply well to
growing clonal populations such as cancers. An example
of the difficulty of applying these tests to cancer comes
from the work of Pleasance et al. [85], who observed an
elevated dN/dS ratio in known colon cancer cell lineages
yet found this to be nonsignificant as evidence for selection
and noted that the approach is insensitive to small numbers
of selected mutations. Some more recent methods for de-
tecting selection may be more promising: Fraser [82] has
recently described approaches employing gene expression
data to detect selection in cancer, and Illingworth et al. [86]
have proposed novel theoretical methods for distinguishing
driver and passenger mutations using time series sequence
data from an evolving clonal population that may also be
applicable to cancer.
In evolution experiments with microbes, the strength
of selection, i.e. the magnitude of the fitness difference
between genotypes, can be estimated directly by measuring
the relative growth of two genotypes in direct competition
under replicated, controlled conditions (e.g., [87–89]). The
power and precision afforded by these approaches havedirectly demonstrated that even mutations of very small
selective effect can spread through large populations (e.g.,
[90]) as predicted by evolutionary theory. Moreover, longi-
tudinal fitness data of this kind from experimental popu-
lations have provided strong evidence for competition
Current Biology Vol 22 No 17
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(reviewed in [33]), a subject with implications for cancer
which we discuss below. The magnitude of selection on
cancer-causing mutations remains largely unexplored and
clearly requires further work (but see [51]). It may be possible
to estimate the selective advantage of cancer cells in vitro
using competition experiments similar to those developed
in experimental evolution. An obvious concern with such
an approach, however, is that in vitro cell culture conditions
need not correspond to the in vivo conditions that would
favor certain mutations in a neoplasm. This is in contrast
to the situation in microbial experimental evolution, where
in vitro conditions can be in vivo conditions.
A further complication in assessing the relative effects of
mutations that cause cancer is that the magnitude and
even the sign of selection affecting a given mutation can
vary depending upon other mutations that have occurred in
the same genetic background. Such epistatic effects are
likely to be especially important in clonal populations, where
mutations are effectively trapped in the genetic background
on which they have arisen. There is rapidly growing evidence
from studies in experimental evolution for epistasis among
beneficial mutations (e.g., [66,91–95]). In cancer, there is
emerging evidence for epistasis from studies of the temporal
sequence of mutations in clones. One example comes from
Barrett’s esophagus, a chronic condition in which the normal
squamous lining of the esophageal epithelium is replaced by
columnar metaplasia which can lead to esophageal adeno-
carcinoma. In Barrett’s patients who progress to cancer, a
CDKN2A (p16) mutation tends to be an initiating lesion and
TP53 (p53) mutations are usually found closer to the devel-
opment of cancer [96,97]. This implies that a p53 mutation
is more beneficial to cells in the context of a p16 mutation
(or perhaps some other, undefined ‘early’ mutation) than it
is alone. Further specific evidence for epistasis in cancer is
provided by a very recent study of clonal ordering and prog-
nosis in acute myeloid leukemia (AML) [98]. In a large cohort
of AML patients for whom outcomes were known, Patel et al.
sequenced all of the mutations known to be relevant to
prognosis: they showed that NPM1 mutations, which have
been associated with improved clinical outcomes, improve
prognosis only in the presence of wild-type FLT3, and then
only if a particular mutation is present in IDH2 [98]. More
broadly, the potential importance of epistasis in cancer
is illustrated by the phenomenon of ‘oncogene addiction’
[99], in which the presence of a prior oncogenic mutation
determines whether a later mutation will act as a driver (be
selectively favoured) or, in contrast, be highly deleterious
to the tumour. Interestingly, a somewhat parallel phenom-
enon has been observed in bacterial populations, in which
certain mutations which compensate for the cost of antibi-
otic resistance are deleterious in the absence of the resis-
tance mutation [100]. In general, epistasis may well play an
important role in cancer evolution, but because the total
number of mutations involved in cancers and their epistatic
effects have yet to be fully characterised, that role largely
remains to be determined.
Ideally, analyses of selection in cancer would lead to
an understanding of both the exact mutations involved in
cancer development and the likely order in which those
mutations accumulate as a cancer develops. Although there
have been some influential attempts to identify predictable
mutational pathways to carcinogenesis [101], simulations
of cancer evolution indicate that the temporal order of evena known set of mutational substitutions during cancer evolu-
tion can be quite variable and need not be replicated across
independent cancers in the absence of epistasis [102]. More-
over, some empirical studies suggest that there are multiple
redundant pathways to cancer [103] with only minimal over-
lap in the mutations that occur between different tumors,
such that identifying common pathways to cancer may be
more difficult than originally supposed.
Mutagenesis and Carcinogenesis: Evolutionary
Considerations
The relationship between mechanisms of mutation and
cancer has obviously been the subject of an enormous
amount of research for many decades. It is well known that
cancer cells often harbour extensive changes in genomic
architecture (such as major chromosomal rearrangements
and aneuploidies) in addition to point mutations [85,104–
106], and recent genomic sequence data suggest the possi-
bility that different cancer types have different mutational
spectra [106,107]. Experimental evolution studies in yeast
have provided evidence for the role that rearrangements,
duplications, and other major chromosomal alterations can
play in the adaptation of eukaryotic genomes to novel
environments (e.g., [15–17]), suggesting a useful parallel
between these studies and cancer evolution. Nonetheless,
there is a limit to what microbial experimental evolution
can reveal about the mechanistic importance of the spe-
cific mutations that are found in cancer cells because the
nature and functional significance of mutational changes
in experimental populations of single-celled microbes can
never completely parallel those in a complex multicellular
organism. Microbial evolution approaches have, however,
contributed significantly to our broad understanding of
how genomic mutation rates evolve in clonal populations,
with some important implications for understanding cancer.
In this section, we focus at this general level on mutation
rates, their evolution, and their consequences for evolution
in clonal populations, including cancers.
Lynch [108] has provided a comprehensive review of mu-
tation rates in normal human cells. In keeping with the dele-
terious nature of most mutations that affect the phenotype,
estimated per nucleotide mutation rates per cell division in
the human germ line are quite low (0.06 x 1029) — lower
than those, for example, in E. coli (0.26. x 1029) and Saccha-
romyces cerevisiae (0.33 x 1029). However, when the number
of germ line generations is taken into account the human
per nucleotide mutation rate per organismal generation
(12.8 x 1029) is far higher than that of microbes. Remarkably,
the per nucleotide per cell divisionmutation rate (0.77 x 1029)
in human somatic cells appears to be much higher than
in germ cells; as yet, the molecular basis for this difference
between somatic and germ line mutation rates is unknown.
Despite the widely accepted association between genome
instability and cancer, it is unclear whether mutation rates
in cancer cells are always elevated above those in normal
somatic cells [109]. Difficulties arise here in that it is more
challenging to measure the actual somatic mutation rate
than to measure the rate at which mutations are substituted
in a population: while the origination of cancer-causing mu-
tations is a haphazard process, their substitution depends
on the dynamics of selectionwithin a tumour. Good evidence
supporting a role for elevated somatic mutation rates in
cancer [1,110] comes, for example, from the observed
hereditary predisposition toward cancer in individuals
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[111]). On the other hand, a recent sequence-based study
[112] estimated a point mutation rate in colorectal cancer
that is comparable to thatmeasured in normal cells by similar
means (4.6 x 10210 vs. 10 x 10210), supporting the notion that
an elevated mutation rate is not needed for cancer
evolution [109,113].
Experimental evolution studies in E. coli have shown that
high genomic mutation rates can evolve in clonal popula-
tions by a process in which spontaneously originated muta-
tor alleles hitchhike to fixation with beneficial mutations
[7,114–116]; the results of these studies are broadly sup-
ported by theoretical work modeling the mutator hitchhiking
process [31,41,117–119]. Taken together, this work suggests
the possibility that mutation rates may indeed become ele-
vated by a similar process in cancers. However, whether
the rate of adaptation (or cancer progression) is significantly
increased at a higher mutation rate is a more subtle issue
[33]. If beneficial mutations are rare within a tumour (Fig-
ure 2A), then an increase in the mutation rate can shorten
the waiting time between them and greatly increase their
rate of incorporation into a clonal population. However, if
beneficial mutations are quite common within a tumour
(Figure 2C), then the rate of adaptation (or cancer progres-
sion) can be limited by the sorting process that takes place
amongst competing clones rather than by the mutation
supply rate [120]. Studies in experimental bacterial popula-
tions have shown that as the supply rate of beneficial muta-
tions is increased to very high values, further increase in the
rate of adaptation is stymied by this process of ‘clonal inter-
ference’ (reviewed in [33], but see [121]). Thus, an increase in
the genomic mutation rate need not necessarily translate
into faster adaptation or faster cancer progression.
There is a growing body of evidence that tumours are
genetically heterogeneous and that this reflects the pres-
ence of multiple cancer-related lesions in some cases.
Such heterogeneity can arise as a result of a high beneficial
mutation supply rate but may also be contributed to by
spatial structure within a tumour (see below). Cancer pro-
gression in such circumstances may well be slowed by the
kind of clonal interference dynamics described above, and
this perhaps offers avenues for treatment of early stage
cancers: it is conceivable that the application of multiple
benign external selection pressures to an early-stage cancer
via drug treatment could delay further progression as a con-
sequence of clonal interference. A test of this idea in exper-
imental yeast populations has provided some encouraging
results [122].
Increasing the genomicmutation rate increases the supply
of deleterious mutations as well as of those that are neutral
and beneficial. A considerable body of theoretical work
in evolutionary genetics is devoted to understanding the
effects of deleterious mutation accumulation on the fitness
and persistence of clonal (asexual) populations [123–129],
and there has been particular interest recently in the possi-
bility that mutagenesis could be used to cure or inhibit
viral infections by decreasing viral fitness within individual
hosts. For example, the antiviral ribavirin is widely used to
treat hepatitis C and is thought to decrease viral titer by
increasing the mutation rate [130]. Similarly, in tumour cell
populations that already have high mutation rates it is
conceivable that an appropriate therapy could drive the
tumour extinct or greatly suppress its growth by raising the
mutation rate even higher [131–133]. Interestingly, severalwidely used anticancer therapies (examples include 5-fluo-
rouracil and temozolomide) are mutagenic. Perhaps some
of their effectiveness is due to the indirect effect they have
in increasing the supply of deleterious mutations in the
tumour population. On the other hand, it has been suggested
that a tumour could garner additional driver mutations and
spread even more rapidly with an artificially elevated muta-
tion rate, so caution is clearly warranted in considering
such an approach [133].
Evolution of Drug Resistance
A fundamental tenet of evolutionary theory is that popula-
tions do not respond to a selection pressure by producing
new, ‘directed’ beneficial mutations specifically suited to
that selection pressure; instead, evolutionary adaptation
occurs via sorting among genetic variants that have arisen
without regard to adaptive utility. This is, in fact, one clear
area where experimental evolution should inform cancer
biology. Whether or not mutations are directed has been
extensively debated in the context of experimental evolution
(reviewed in [134,135]), and the prevailing consensus con-
tinues to be that mutations arise indifferently with respect
to selective need (although the possibility of directed muta-
tion has been raised again in recent experiments [11]). In
this respect, it is important to remember that there is also
no evidence that therapeutic resistance in cancer arises in
response to the selective pressure of therapy; instead, muta-
tions conferring resistance are likely to exist within a popula-
tion of cancer cells and are subsequently selected for when
cancer therapy is applied. This principle has been demon-
strated in the case of several therapies (e.g. [71,136–140]).
It is possible, of course, that some mutations may arise
during the course of therapy if the therapy is not completely
effective, and population genetics theory has been devel-
oped that can distinguish between the two possibilities
[141,142]. A few studies have suggested that resistance
may develop in some naı¨ve populations of bacteria during
antibiotic application [143] while work in HIV has elegantly
demonstrated that, most of the time, resistance mutations
are present before therapy is applied [144].
Experimental evolution also provides insights into how
therapy regimens should be designed to reduce the inci-
dence and development of resistance. The development of
resistance depends critically on parameters such as popula-
tion size, mutation rate, and selective effect of the adaptive
mutations [142]. For instance, lower-dose, pulsed therapy
can drive the development of resistance, as has been
demonstrated for evolution of antibiotic resistance [145],
particularly with suboptimal dosing (e.g., [146]), and with
resistance to malaria [147]. Theoretical evolutionary models
suggest that this is also likely to be a problem for cancer ther-
apies and that we should reevaluate the common dosing
schedules of chemotherapeutic agents [148,149].
The Microenvironment: Spatial Structure and Cell–Cell
Interactions
To date, most experimental evolution and the theoretical
work it has stimulated have assumed a set of environmen-
tal conditions that might be termed the ‘planktonic ideal’:
well-mixed (zero-dimensional) liquid cultures (Figure 1A,B).
The planktonic ideal has been invaluable for working out
fundamental evolutionary dynamics. But cancers do not
necessarily conform to the well-mixed, cell-autonomous
ideal; neoplasms are three-dimensional objects with
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cells can interact with each other and theirmicroenvironment
[152,153]. Recent theoretical studies show that spatial struc-
ture can have important consequences for the speed of
adaptation or cancer progression. Neoplasms in which cells
remain in one place are predicted to take longer to progress
to cancer than those in which cells are highly motile [9].
This is because the limiting effect of clonal interference
on the rate of adaption is augmented in the presence of
spatial structure [9]; long-range migration can mitigate this
effect and increase the rate of adaptation or neoplastic
progression [10].
As mentioned in a previous section, high levels of genetic
heterogeneity within tumours and pre-neoplasias are in-
creasingly reported [71,106,154–158]. Evolution experiments
with microbes have provided insights into how spatial
structure and interactions between cells may explain in-
trapopulation heterogeneity. For example, Kerr et al. [159]
demonstrated that three bacterial clones could coexist in a
stable nontransitive, competitive relationship (rock–paper–
scissors) in a spatially structured environment whereas this
relationship was unstable in a well mixed environment. In
Pseudomonas fluorescens, populations grown in spatially
structured environments showed sustained levels of hetero-
geneity, while those grown in homogeneous environments
did not [160]. Even in the well mixed environment of serial
culture or the chemostat (Figure 1A,B), homogeneous ances-
tor populations of bacteria have evolved into distinct, stable
subclones inwhich each subclone depends on themetabolic
byproducts of another in a process called cross-feeding
[161–164]. Bacteria can also live in matrix-encased, cooper-
ative, multicellular communities called biofilms (described
in [165]). In one study, several different heritable phenotypes
of clones were observed in Pseudomonas aeruginosa bio-
films, including one cancer-like clone that developed faster
and was more resistant to treatment than the other clones
measured in the biofilm [166]. Intriguingly, biofilm communi-
ties often exhibit increased resistance to treatment by anti-
microbial agents [167]. Cell–cell interactions and spatial
structure are clearly important aspects of neoplasms, and
so it is worth considering whether general interclonal rela-
tionships of the kind we have discussed here apply within
neoplasms as well.
Concluding Perspective
So far, the evolutionary approach to understanding cancer
has focused mainly on the analysis of patterns of standing
genetic variation within tumours. In this review, we have tried
to draw insights on cancer biology from the large and rapidly
growing field of microbial experimental evolution, which
studies evolution in real time. In making this broad connec-
tion, our rationale has been that cancer may be usefully
understood as an evolutionary phenomenon of clonal popu-
lations with important dynamical similarities to microbial ex-
perimental evolution and that the phenomenological power
of experimental evolution can provide insights into these
dynamics that are not as readily available from in vivo studies
of cancer.
Fundamentally, of course, microbial experimental evolu-
tion can only serve as a model system or analogy for can-
cer development. In any analogy, the differences between
entities being compared can be as important as the similar-
ities. We have not specifically discussed the evolution of
metastasis in this review because there is very little in theexperimental evolution literature to date that is directly appli-
cable to this problem. Another obvious topic that we have
ignored in this review is the role of epigenetic changes in
cancer development. There has not been a significant body
of work in experimental evolution in this area so far. If epige-
netic changes are completely stable in cancers, then the
dynamics of ordinary mutations as described above pro-
vide a useful analogy; however, if epigenetic changes are
unstable, then their theoretical and experimental study will
require new approaches differing from those we have dis-
cussed— this may well be an important area in which exper-
imental evolution and theory can contribute hand-in-hand in
the near future.
We end our review on a more speculative note. A vast
amount of research has focused on the molecular genetic
bases of cancer for many decades now and enormous
advances have clearly been made, yet the progression of
any individual cancer remains difficult to predict [2,3,168].
The problem of predicting cancer based on explicit knowl-
edge of its genetic bases can be regarded more generally
as the problem of predicting evolution given the large
number ofmutations that may occur in a population and their
potential interactions in determining fitness. Here, we briefly
describe new theoretical work by two of us [12] that explores
a framework for forecasting the near-future evolution of
adapting populations that does not rely on detailed knowl-
edge of the underlying genetics of adaptation.
A commonplace metaphor in the evolution literature is the
‘adaptive landscape’, which is conceptually a topographic
mapping of fitness (vertical axis) onto all possible mutational
combinations in a population. Fitter genotypes correspond
to higher elevations in the topography, and a population
located anywhere on the map ascends the local slope by
natural selection to the nearest peak, much as amountaineer
ascends amountain. Although the adaptive landscapemeta-
phor is a useful way of thinking about evolution, it has
a glaring practical problem: namely, the near impossibility
of obtaining the real map relating all possible mutational
combinations to fitness in an organism (or cancer) for any
given environment (individual), let alone across environ-
ments (individuals).
In contrast to the adaptive landscape approach, our recent
theoretical work focuses on the mountaineer rather than the
mountains. Just as amountaineer’s gait and pacemay reveal
something about the terrain underfoot, an evolving popula-
tion’s composition can carry information about the under-
lying adaptive landscape and even about what lies a few
paces ahead. We have shown that by sampling members of
a population in real time and characterising the population’s
fitness distribution at multiple time points, evolution can
successfully be predicted tens of generations into the
future in simulations [12], experimental E. coli populations
(Sprouffske et al.,manuscript in preparation) and, potentially,
cancer lineages. This approach might be applicable to the
analysis and prediction of cancer progression within indi-
vidual patients, though we caution that its practicability and
scope require considerable further research. Nonetheless,
the potential of this approach is, we think, illustrative of the
main point of our review: namely, that evolution experiments
with microbes may have new things to tell us about cancer.
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